Page 46 - SAHCS HIVMed Journal Vol 20 No 1 2019

Page 17 of 26 Guideline

Disclaimer 26. Hoffmann CJ, Fielding KL, Johston V, et al. Changing predictors of mortality over
time from cART start: Implications for care. J Acquir Immune Defic Syndr.
The views and opinions expressed in this guideline are those 2011;58(3):269–276. https://doi.org/10.1097/QAI.0b013e31823219d1
of the authors and do not necessarily reflect the official policy 27. Yiannoutsos CT, Johnson LF, Boulle A, et al. for the International Epidemiologic
Databases to Evaluate AIDS (IeDEA) Collaboration. Estimated mortality of adult
or position of any affiliated agency of the authors. HIV-infected patients starting treatment with combination antiretroviral therapy.
Sex Transm Infect. 2012;88(suppl 2):i33–i43. https://doi.org/10.1136/
sextrans-2012-050658
References 28. Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The use of the nitrogen
mustards in the palliative treatment of carcinoma – With particular reference to
bronchogenic carcinoma. Cancer. 1948;1(4):634–656. https://doi.
1. South African Department of Health. National policy framework and strategy on org/10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L
palliative care, 2017–2022. Final draft. Pretoria, Gauteng: South African 29. The Support and Palliative Care Indicator Tools (SPICT ) [homepage on the
TM
Department of Health; 2017. Internet]. University of Edinburgh, SPICT ; 2015.[cited 03 Nov 2019]. Available
TM
2. WHO Definition of Palliative Care. World Health Organization (WHO). Palliative from: http://www.spict.org.uk
care factsheet. No date. [cited 2017 Nov 19]. Available from: http://www.who.int/ 30. Tate JP, Justice AC, Hughes MD, et al. The VACS index: An internationally
cancer/palliative/definition/en/. generalizable risk index for mortality after one year of antiretroviral therapy. AIDS.
3. Cassel EJ. The nature of suffering and the goals of medicine. 2nd ed. New York: 2013;27(4):563–572. https://doi.org/10.1097/QAD.0b013e32835b8c7f
Oxford University Press, 2004; p. 31. 31. Justice AC, Modur S, Tate JP, et al. for the NA-ACCORD and VACS Project Teams.
4. UNAIDS Data 2017 [homepage on the Internet]. HIV and AIDS in South Africa. Predictive accuracy of the Veterans Aging Cohort Study (VACS) index for mortality
[cited 2018 Jan 05]. Available from: http://www.avert.org with HIV infection: A North American Cross Cohort Analysis. J Acquir Immune Defic
5. STATS SA. 2017 [cited 2017 Oct 10]. Available from: http://www.statssa.gov.za Syndr. 2013;62(2):149–163. https://doi.org/10.1097/QAI.0b013e31827df36c
6. Spencer DC. Personal communication with colleagues in the hospitals of Gauteng, 32. Gustafson DR, Shi Q, Holman S, et al. Predicting death over 8 years in a prospective
cohort of HIV-infected women: The women’s interagency HIV study. BMJ Open.
Mpumalanga and the Free State. 2018. 2017;7:e013993. https://doi.org/10.1136/bmjopen-2016-013993
7. Welz T, Hosegood V, Jaffar S, et al. Continued very high prevalence of HIV infection
in rural KwaZulu-Natal, South Africa: A population-based longitudinal study. AIDS. 33. Merlin J, Pahuja M, Selwyn PA. Issues in HIV/AIDS in adults in palliative care
2007;21(11):1467–1472. https://doi.org/10.1097/QAD.0b013e3280ef6af2 [homepage on the Internet]. Section Editor: R Sean Morrison. UpToDate. [cited 01
February 2018, August 2019]. Available from: www.Uptodate.com/contents/
8. Black A, Sitas F, Chibrawara T, Gill Z, Kubanje M, Williams B. HIV-attributable causes isses-in-adults-in-palliative-care.
of death in the medical ward at Chris Hani Baragwanath Hospital, South Africa.
PLoS One. 2019;14(5):e0215591. https://doi.org/10.1371/journal.pone.0215591 34. Codes 168S and 260S, for HIV infection and imminent deaths, the prescribed
minimum benefits, the Medical Schemes Act 131 of 1998 of the Republic of South
9. Wong EB, Omar T, Setlhako GJ, et al. Causes of death on antiretroviral therapy: A Africa, Pretoria. [cited 01 February 2018]. Available from: https://wwwsemdsa.
post-mortem study from South Africa. PLoS One. 2012;7(10):e47542 https://doi. org.za and pmb_consumerguidebooklet.pdf.
org/10.1371/journal.pone.0047542 35. Board of Health Funders. Rosebank, Gauteng. [cited 2017 Mar 2016]. Available
10. Van Rie A, Westreich D, Sanne I. Tuberculosis in patients receiving antiretroviral from: http://www.medicalschemes.com/files/Circulars/circular21of2017.pdf.
treatment. J Acquir Immune Defic Syndr. 2011;56(4):349–355. https://doi.
org/10.1097/QAI.0b013e3181f9fb39 36. Turck DC, Wilson HD, Cahana A. Treatment of chronic non-cancer pain. Lancet.
11. Richards L. Unpublished data collected and tabulated for the Degree of M.Med 2011;377:2226–2235. https://doi.org/10.1016/S0140-6736(11)60402-9
(Internal Medicine) from the University of the Witwatersrand, Johannesburg. 2018. 37. World Health Organization (WHO). Cancer pain relief. 2nd ed. Geneva: World
12. Lunney JR, Lynn J, Foley DJ, Lipson S, Guralnik JM. Patterns of functional decline at the Health Organization; 1996.
end of life. JAMA. 2003;289:2387–2392. https://doi.org/10.1001/jama.289.18.2387 38. Blinderman CD, Billings JA. Comfort care for patients dying in the hospital. N Eng J
13. Gawande A. Figure (un-numbered) on pg 25, Cpt 2, In ‘Being Mortal’, Published by Med. 2015;373:2549–2561. https://doi.org/10.1056/NEJMra1411746
Profile Books Ltd., in association with the Wellcome Collection, 183 Euston Road, 39. Bruce RD, Merlin J, Lum PJ, et al. 2017 HIVMA of IDSA clinical practice guidelines
London. Second edition published, 2015. for the management of chronic pain in patients living with HIV. Clin Infect Dis.
14. Simms V, Higginson IJ, Harding R. Integration of palliative care throughout HIV 2017;65(10):e1–e3. https://doi.org/10.1093/cid/cix636
disease. Lancet Infect Dis. 2012;12:571–575. https://doi.org/10.1016/S1473- 40. Portenoy RK. Treatment of cancer pain. Lancet. 2011;377:2236–2247. https://doi.
3099(12)70085-3 org/10.1016/S0140-6736(11)60236-5
15. Jambo KC, Banda DH, Afran L, et al. Asymptomatic HIV-infected individuals on 41. Compton WM, Jones CM, Baldwin GT. Relationship between nonmedical
antiretroviral therapy exhibit impaired lung CD4+ T-cell responses to mycobacteria. prescription-opioid use and heroin use. N Engl J Med. 2016;374:154–163. https://
Am J Resp Crit Care Med. 2014;190(8):938–947. https://doi.org/10.1164/
rccm.201405-0864OC doi.org/10.1056/NEJMra1508490
16. Almodovar S. The Complexity of HIV persistence and pathogenesis in the lung 42. Knaul FM, Farmer PE, Krakauer EL, et al. on behalf of the Lancet Commission on
under antiretroviral therapy: Challenges beyond AIDS. Viral Immunol. Palliative Care and Pain relief Study Group. Alleviating the access abyss in palliative
2014;27(5):186–190. https://doi.org/10.1089/vim.2013.0130 care and pain relief – An imperative of universal health coverage: The Lancet
Commission Report. Lancet. 2018;391:1391–1454. https://doi.org/10.1016/
17. Ferrand RA, Desai SR, Hopkins C, et al Chronic lung disease in adolescents with S0140-6736(17)32513-8
delayed diagnosis of vertically acquired HIV infection. Clin Infect Dis.
2012;55(1):145–152. https://doi.org/10.1093/cid/cis271 43. Chang E, Sekhar R, Patel S, Balasubramanyam A. Dysregulated energy expenditure
18. Desai SR, Nair A, Rylance J, et al. Human immunodeficiency virus-associated in HIV-infected patients: A mechanistic review. Clin Infect Dis. 2007;44:1509–
1517. https://doi.org/10.1086/517501
chronic lung disease in children and adolescents in Zimbabwe: Chest radiographic
and high-resolution computed tomographic findings. Clin Infect Dis. 44. Mangili A, Murman DH, Zampini AM, Wanke CA. Nutrition and HIV infection:
2018;66(2):274–281. https://doi.org/10.1093/cid/cix778 Review of weight loss and wasting in the era of highly active antiretroviral therapy
19. Maddocks M, Lovell N, Booth S, Man WD-C, Higginson IJ. Palliative care and from the nutrition for healthy living cohort. Clin Infect Dis. 2006;42:836–842.
https://doi.org/10.1086/500398
management of troublesome symptoms for people with chronic obstructive
pulmonary disease. Lancet. 2017;390:988–1002. https://doi.org/10.1016/S0140- 45. Argemi X, Dara S, You S, et al. Impact of malnutrition and social determinants on
6736(17)32127-X survival of HIV-1 infected adults starting antiretroviral therapy in resource-limited
20. Drummond MB, Kirk GD. HIV-associated obstructive lung diseases: Insights and settings. AIDS. 2012;26:1161–1166. https://doi.org/10.1097/QAD.0b013e328353f363
implications for the clinician. Lancet Respir Med. 2014;2(7):583–592. https://doi. 46. Rabkin JG, Wagner GJ, Rabkin R. A double-blind, placebo-controlled trial of
org/10.1016/S2213-2600(14)70017-7 testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen
21. May MT, Gompels M, Delpech V, et al. Impact on life expectancy of HIV-1 positive Psychiatry. 2000;57:141. https://doi.org/10.1001/archpsyc.57.2.141
+
individuals of CD4 cell count and viral load response to antiretroviral therapy. 47. Chung KF, Pavord ID. Prevalence, pathogenesis, and causes of chronic cough.
AIDS (London, England). 2014;28(8):1193–1202. https://doi.org/10.1097/
QAD.0000000000000243 Lancet. 2008;371:1364–1374. https://doi.org/10.1016/S0140-6736(08)60595-4
22. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with 48. Walzer PD, Evans HER, Copas AJ, et al. Early predictors of mortality from
metastatic non-small-cell lung cancer. N Engl J Med. 2010;363:733–742. https:// Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985–2006. Clin Infect
doi.org/10.1056/NEJMoa1000678 Dis. 2008;46:625–633. https://doi.org/10.1086/526778
23. Gazzola L, Tincati C, Bellistri GM, et aL. The absence of CD4+ T cell count recovery 49. Powell K, Davis JL, Morris AM, et al. Survival for patients with HIV admitted to the
despite receipt of virologically suppressive highly active antiretroviral therapy: ICU continues to improve in the current era of combination antiretroviral therapy.
Clinical risk, immunological gaps and therapeutic options. Clin Infect Dis. Chest. 2009;135(1):11–17. https://doi.org/10.1378/chest.08-0980
2009;48:328–3724. https://doi.org/10.1086/595851 50. Guidelines in post-exposure prophylaxis for HIV and the use of co-trimoxazole
24. Serrano-Villar S, Sainz T, Lee SA, et al. HIV-infected individuals with low CD4/CD8 prophylaxis for HIV-related infections among adults, adolescents and children:
ratio despite effective antiretroviral therapy exhibit altered T cell subsets, recommendations for a public health approach – December 2014 supplement to
heightened CD8+ T cell activation and increased risk of non-AIDS morbidity and the 2013 consolidated guidelines on the use of antiretroviral drugs for treating
mortality. PLoS Pathog. 2014;10(5):e1004078. https://doi.org/10.1371/journal. and preventing HIV infection. Geneva: World Health Organization, 2014.
ppat.1004078 (https:www.who.int/hiv/pub/guidelines/arv2013supplement_dec2004/en.)
25. Nanzigu S, Kiguba R, Kabanda JK, et al. Poor immunological recovery among 51. Insight START Study Group. Initiation of antiretroviral therapy in early
severely immunosuppressed antiretroviral therapy-naïve Ugandans. HIV-AIDS Res asymptomatic HIV infection. N Engl J Med. 2015;373:795–807. https://doi.
Palliative Care. 2013;5:309–319. https://doi.org/10.2147/HIV.S50614 org/10.1056/NEJMoa1506816
http://www.sajhivmed.org.za 39 Open Access